Preview Mode Links will not work in preview mode

This Week in Cardiology

Jul 28, 2023

Antiarrhythmic drugs in patients with CAD, observational studies, GLP-1 agonists, and the subcutaneous ICD are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

I. AAD in Patients with CAD

- The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease

- Three Questions for Evidence-Based Cardiac Electrophysiology

- The Cardiac Arrhythmia Suppression Trial (CAST)

II. GLP-1 Agonists

Tirzepatide Powers Weight Loss in Two More Pivotal Trials

Semaglutide Use Surges in US Adults With Type 2 Diabetes

- Tirzepatide Once Weekly for the Treatment of Obesity

- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial


S-ICD Shows Virtues, Limits in 'Real World' Postmarket Study

- Postapproval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System

- Subcutaneous or Transvenous Defibrillator Therapy

- Letter to the Editor

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact